Page last updated: 2024-08-17

prednisone and docetaxel anhydrous

prednisone has been researched along with docetaxel anhydrous in 252 studies

Research

Studies (252)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (1.19)	18.2507
2000's	60 (23.81)	29.6817
2010's	157 (62.30)	24.3611
2020's	32 (12.70)	2.80

Authors

Authors	Studies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Francis, PA; Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR; Venkatraman, ES; Woolley, K	1
Ohnishi, K; Ohno, R	1
Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C	1
Carpino, A; Cognetti, F; D'Ottavio, AM; Ferraresi, V; Giannarelli, D; Marsella, A; Milella, M; Nisticò, C; Papaldo, P; Terzoli, E; Thorel, MF; Vaccaro, A	1
Beer, TM; Bubalo, JS	1
Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R	1
Heine, K; Wolff, JM	1
Berry, WR; Chi, KN; de Wit, R; Eisenberger, MA; Horti, J; James, ND; Oudard, S; Pluzanska, A; Rosenthal, MA; Tannock, IF; Théodore, C; Turesson, I	1
Benson, MC; Berry, D; Burch, PA; Crawford, ED; Hussain, MH; Jones, JA; Kohli, M; Lara, PN; Moinpour, C; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME	1
Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R	1
Areal, J; Arroyo, FR; Constenla, M; Font, A; Martin, C; Murias, A; Rosell, R; Saladie, JM; Sanchez, JJ; Santiago, JA	1
Itoh, N	1
de Wit, R	2
Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E	1
Van Poppel, H	1
George, DJ; Moore, CN	1
Ferrero, JM	1
Doggrell, SA	1
Berry, WR	1
Petrylak, DP	4
Kibel, AS	1
Protheroe, A	1
Sleijfer, S; Stoter, G	1
Batman, E; de Wit, R	1
Patel, AR; Pienta, KJ; Sandler, HM	1
Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME	1
Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV	1
Chang, SS; Rumohr, JA	1
Fortner, BV; Houts, AC; Schwartzberg, LS	1
Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R	1
Kovel, S; Sella, A; Skoneczna, I; Sternberg, C; Yarom, N	1
Gross, M; Hussain, MH; Hutcheon, D; Kelly, WK; Michaelson, D; Rosenberg, JE; Small, EJ; Weinberg, VK; Wilding, G	1
Akaza, H; Hinotsu, S; Joraku, A; Kawai, K; Kojima, T; Miyanaga, N; Oikawa, T; Sekido, N; Shimazui, T	1
Armstrong, AJ; Carducci, MA; de Wit, R; Eisenberger, M; Garrett-Mayer, E; Ou Yang, YC; Tannock, I	1
Fan, XR; Ji, ZG; Li, HZ; Shi, BB; Xia, M; Xiao, H; Yan, WG; Zhou, Y	1
Bladou, F; Gravis, G; Salem, N; Viens, P	1
Armstrong, AJ; de Wit, R; Eisenberger, M; Garrett-Mayer, ES; Tannock, IF; Yang, YC	1
Dai, B; Shen, YJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhang, W; Zhu, Y	1
Aitini, E; Andreuccetti, M; Antonuzzo, A; Barbieri, R; Di Marsico, R; Falcone, A; Fontana, A; Fontana, E; Galli, C; Galli, L; Landi, L	1
Burzykowski, T; Buyse, M; Collette, L	1
Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Soban, F; Tannock, IF	1
Hussain, M; Vaishampayan, U	1
Chaladaj, A; Droz, JP	1
Chambers, C; Cusano, F; Howard, DN	1
Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R	1
Armstrong, AJ; Eisenberger, M; Garrett-Mayer, EL	1
Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Roessner, M; Tannock, AI	1
Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Tannock, IF	1
Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E	1
Armstrong, AJ; de Wit, R; Eisenberger, M; Halabi, S; Tannock, IF	1
Bonny, MA; Clausse, M; D'Hondt, L; Dopchie, C; Duck, L; Filleul, B; Honhon, B; Jousten, P; Kerger, J; Machiels, JP; Marcelis, L; Mazzeo, F; Moxhon, AM; Tombal, B; Verhoeven, D; Verschaeve, V	1
Kovel, S; Sella, A; Skoneczna, I; Sternberg, CN	1
Donaldson, GW; Moinpour, CM; Nakamura, Y	1
Zhang, B	1
Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK	1
Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G	1
Agatsuma, T; Fujimoto, K; Hanaoka, M; Koizumi, T; Kubo, K; Urushihata, K; Yamamoto, H; Yasuo, M	1
Gupta, NP; Nayyar, R; Sharma, N	1
Yuasa, T	1
Finter, F; Gust, K; Küfer, R; Rinnab, L	1
Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L	1
Armstrong, AJ; de Wit, R; Eisenberger, M; George, DJ; Halabi, S; Tannock, IF	1
Armstrong, AJ; George, DJ	1
Dahut, WL; Figg, WD; Kluetz, PG	1
Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J	1
Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME	1
Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jones, E; Kim, YS; Latham, L; Lee, MJ; Madan, RA; Ning, YM; Parnes, HL; Steinberg, SM; Sun, H; Trepel, JB; Woo, S; Wright, JJ	1
Canil, CM; Chen, EX; Chi, KN; Ernst, S; Hotte, SJ; Juhasz, A; Moore, MJ; Murray, P; Sridhar, SS; Wang, L; Yen, Y; Zwiebel, JA	1
Brunello, A; Extermann, M; Kapoor, R	1
Chi, KN; Eigl, BJ; Eisenhauer, EA; Gleave, ME; Hotte, SJ; North, S; Powers, J; Saad, F; Tannock, I; Tu, D; Yu, EY	1
Lee, HJ; Yun, GW	1
Dorff, TB; Quinn, DI	1
Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L	1
El Bary, NM; El Halim Mohamed Abu Hamar, A; El Shebiney, M; Mansour, S; Maria, A; Sadaka, E	1
Figg, WD	1
Pal, SK; Sartor, O; Twardowski, P	1
Alamanis, C; Anastasiou, I; Bamias, A; Bournakis, E; Chrisofos, M; Constantinides, C; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Karadimou, A; Mountzios, I; Papadimitriou, C; Tsiatas, M; Varkaris, A; Wen, S	1
Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R	1
Altieri, V; Buonerba, C; Cavaliere, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Ferro, M; Perdonà, S; Puglia, L; Rescigno, P	1
Bracarda, S; Logothetis, C; Oudard, S; Sternberg, CN	1
Albers, P; Berry, WR; Chi, K; Chu, L; de Wit, R; Heidenreich, A; Heller, G; Henick, B; Jia, X; Meluch, AA; Nordquist, LT; Rosen, PJ; Ruether, DJ; Scher, HI; Venner, PM; Waterhouse, D	1
Rexer, H	2
Cicero, G; De Luca, R	1
Armstrong, AJ; Berry, WR; Brookes, M; de Wit, R; Eisenberger, MA; Leopold, L; Pond, GR; Sonpavde, G; Tannock, IF; Wood, BA	1
Berry, S; Chi, K; Czaykowski, P; Eigl, B; Gleave, M; Hotte, S; Lattouf, JB; Mukherjee, SD; North, S; Pollak, M; Saad, F; Winquist, E; Wood, L	1
Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ	1
Shen, Y; Ye, D	1
Alexandre, J; Bousquet, G; de Mont-Serrat, H; Faivre, S; Goldwasser, F; Kaiser, R; Le Tourneau, C; Misset, JL; Raymond, E	1
Kawaguchi, K; Kinebuchi, Y; Suzuki, A; Tsuruta, T; Wajiki, M	1
Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA	1
Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M	1
Asmar, L; Awasthi, S; Beer, TM; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Kolodziej, M; Martincic, D; Rastogi, A; Rauch, MA; Rousey, SR; Sonpavde, G; Wang, Y; Weinstein, RE	1
Carducci, M; George, D; Halabi, S; Kantoff, P; Kaplan, E; Kelly, WK; Mahoney, JF; Monk, JP; Morris, M; Small, EJ; Stadler, WM; Vogelzang, NJ	1
Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA	1
Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED	1
Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S	1
McKeage, K	1
Bian, XJ; Dai, B; Shen, YJ; Xie, HY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y	1
Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA	1
Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M	1
Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M	1
Pal, SK; Sartor, O	1
Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN	1
Arévalo, E; Carranza, OE; Castañón, E; Castillo, A; Collado-Gómez, V; Fusco, JP; Gil-Aldea, I; Gil-Bazo, I; López, I; Zudaire, ME	1
Saylor, PJ	1
Aragon-Ching, J; Beatson, M; Chau, CH; Dahut, WL; Figg, WD; Gao, R; Gulley, JL; Madan, RA; Sissung, TM; Spencer, S; Steinberg, SM	1
Arén, O; Bavbek, S; Birtle, A; Elliott, T; Fizazi, K; Fléchon, A; Gil, T; Gravis, G; Hatteville, L; Ivanov, S; Karlsson, CT; Karyakin, O; Magherini, E; Matveev, V; Orlandi, F; Petrylak, D; Rosenthal, M; Skoneczna, I; Tannock, IF; Tombal, B; Viana, L	1
Clarke, S; Galsky, M; Linton, A; Pond, G; Sonpavde, G; Vardy, J	1
Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM	1
Aggarwal, R; Carducci, M; George, D; Halabi, S; Kantoff, P; Kelly, WK; Mahoney, JF; Millard, F; Monk, JP; Morris, MJ; Small, EJ; Stadler, WM	1
Batty, N; Pili, R; Yarlagadda, N	1
Berruti, A; Caffo, O; Chierichetti, F; Galligioni, E; Maines, F; Palermo, A; Veccia, A	1
Chen, XS; Du, J; Tian, J; Yang, Q; Yao, X	1
Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK	1
de Braud, F; Grassi, P; Procopio, G; Salvioni, R; Testa, I; Torri, V; Valdagni, R; Verzoni, E	1
de Bono, JS; Fizazi, K; Flaig, TW; Goodman, OB; Kheoh, T; Li, J; Molina, A; Mulders, PF; Scher, HI; Suttmann, H	1
Chi, KN; Fizazi, K; Haqq, CM; Higano, CS; Kheoh, T; Li, J; Marberger, M; Molina, A; Mulders, PF; Saad, F	1
Amir, E; Attalla, M; De Gouveia, P; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Moore, M; Pond, GR; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE; Wang, L	1
Armstrong, AJ; de Bono, J; Halabi, S; Kaplan, EB; Lin, CY; Oudard, S; Petrylak, D; Sartor, O; Shen, L; Small, EJ; Sternberg, CN	1
Aziz, R; Ghosh, D; Ibrahim, A; Justice, R; Kluetz, PG; Maher, VE; Mehrotra, N; Ning, YM; Palmby, T; Pazdur, R; Pfuma, E; Sridhara, R; Tang, S; Tilley, A; Zhang, L; Zirkelbach, JF	1
Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L	1
André, V; Brown, J; Callies, S; Castellano, D; Cervera Grau, JM; Chłosta, PL; Durán, I; Heinrich, B; Hurt, K; Kamradt, J; Lahn, M; Mellado, B; Pikiel, J; Reuter, C; Somer, BG; Stöckle, M; Wedel, S; Wiechno, P	1
Hoy, SM	1
Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA	1
Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL	1
Fizazi, KS; Halabi, S; Kaplan, EB; Kelly, WK; Lin, CY; Morris, MJ; Moul, JW; Small, EJ	1
Abalı, H; Gültepe, I; Köse, F; Mertsoylu, H; Muallaoğlu, S; Özyılkan, Ö; Sezer, A; Sümbül, AT	1
Chia, VM; Langeberg, WJ; Morrow, PK; Page, JH; Siozon, CC	1
Lee, HJ; Ryu, H	1
Boissier, E; Loriot, Y; Massard, C; Vignot, S	1
Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL	1
Inokuchi, J; Kiyoshima, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A	1
Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N	1
Gordian, E; Quintero, C; Ramachandran, K; Reis, IM; Singal, R; Zhao, W	1
Francini, E; Laera, L; Petrioli, R; Rossi, G; Roviello, G	1
Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T	1
Carducci, MA; Friedman, PN; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, FA; Owzar, K; Patel, JN; Ratain, MJ; Small, EJ	1
Amir, E; de Wit, R; Eisenberger, MA; Mercier, F; Rosenthal, M; Sonpavde, G; Tannock, IF; Templeton, AJ; Tombal, B; van Soest, RJ; Vera-Badillo, FE	1
Barroso-Sousa, R; Chaves, AC; da Fonseca, LG; de Castro, G; Dzik, C; Kann, AG; Souza, KT	1
Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A	1
Aggarwal, RR; Alumkal, J; Beer, TM; Graff, JN; Herrera, I; Higano, C; Lin, AM; Nordquist, LT; Ryan, CJ; Small, EJ; Taplin, ME; Weinberg, VK	1
Agarwal, N; Agus, D; Bellmunt, J; Borgstein, N; Carcano, F; Cruz, FM; De Bono, J; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fountzilas, G; Jones, R; Lee, SY; Oudard, S; Petrylak, DP; Saad, F; Tejura, B; Ulys, A; Webb, IJ	1
Chen, SP; Huang, YR; Jie, J; Na, YQ; Sun, Y; Sun, YH; Tian, Y; Wei, Q; Xie, LP; Yang, Y; Yao, X; Ye, DW; Ye, ZQ; Zeng, SX; Zhang, W; Zhang, X; Zhou, FJ; Zhou, T	1
Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T	1
Baumunk, D; Janitzky, A; Liehr, UB; Lux, A; Porsch, M; Reiher, F; Schindele, D; Schostak, M; Seseke, F; Ulrich, M; Wendler, JJ	1
Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ	1
Ndibe, C; Sonpavde, G; Wang, CG	1
Benatar-Haserfaty, J; Durán Paz, S; Moreno Casanova, I	1
Basch, E; Corty, RW; Dusetzina, SB; Green, AK; Meeneghan, M; Milowsky, MI; Reeder-Hayes, KE; Wood, WA	1
Bartolotti, M; Brandes, AA; Cavallo, G; Dalpiaz, G; De Biase, D; Denicolò, F; Di Battista, M; Genestreti, G; Lazzari-Agli, LA; Trisolini, R; Valli, M	1
Cheng, S; Cheon, P; Chow, E; Chow, R; DeAngelis, C; Emmenegger, U; Giotis, A; Lowe, J; McDonald, R; Pasetka, M; Pulenzas, N; Rowbottom, L; Stinson, J; Thavarajah, N	1
Beuzeboc, P; Massard, C	1
Babjuk, M; Bartunkova, J; Becht, E; Bilkova, P; Fucikova, J; Gasova, Z; Horvath, R; Hromadkova, H; Jarolim, L; Kayserova, J; Kubackova, K; Lastovicka, J; Podrazil, M; Rozkova, D; Sochorova, K; Spisek, R; Vavrova, K; Vrabcova, P	1
Armstrong, A; Ferrari, A; Hainsworth, J; Higano, CS; Hozak, RR; Hussain, M; Joshi, A; Kelly, WK; Liu, G; Rathkopf, D; Schwartz, JD; Yang, L	1
Han, WK; He, ZS; Huang, LH; Jin, J; Song, Y; Yang, KW; Yu, W; Zhou, LQ	1
Dickow, B; Fontana, J; Heath, E; Heilbrun, L; Land, S; Li, J; Shevrin, D; Smith, D; Stark, K; Stein, M; Vaishampayan, U	1
Chang, K; Dai, B; Jia, ZW; Kong, YY; Li, GX; Qu, YY; Wang, Y; Ye, DW	1
Carprieaux, M; Rappe, B; Schallier, D; Vandenbroucke, F	1
Bellmunt, J; Davis, ID; de Bono, JS; De Porre, P; Fizazi, K; Griffin, TW; Kheoh, T; Molina, A; Mulders, PF; Oudard, S; Protheroe, A; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Schrijvers, D; Small, EJ; Smith, MR; Taplin, ME; Yu, MK	1
Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S	1
Abrial, C; Atger, M; Bayet-Robert, M; Chollet, P; Curé, H; Durando, X; Eymard, JC; Gadea, E; Guy, L; Mahammedi, H; Planchat, E; Pouget, M; Savareux, L; Thivat, E; Van-Praagh, I	1
de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S	1
Bruce, J; De Porre, P; Gonzalez, MD; Kheoh, T; Lim, EA; Maul, S; Nanus, DM; Peng, W; Petrylak, DP; Posadas, EM; Smit, JW; Tagawa, ST; Tran, N	1
Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA	1
Chen, Z; De Porre, P; Du, C; Feng, Y; Huang, Y; Jin, J; Li, C; Lin, G; Liu, W; Shan, Y; Sun, Y; Sun, Z; Xie, L; Ye, D; Ye, ZQ; Zou, Q	1
Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X	1
Carducci, MA; Dolan, ME; Dorsey, SG; Febbo, PG; Friedman, PN; Furukawa, Y; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Krens, SD; Kroetz, DL; Kubo, M; Lassiter, C; Lessans, S; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, F; Nakamura, Y; Owzar, K; Patel, J; Ratain, MJ; Renn, CL; Shterev, I; Sibley, AB; Small, EJ; Watson, D; Weisman, L; Wheeler, HE; Wing, C	1
Butte, AJ; Geifman, N	1
de Bono, JS; De Porre, P; Fizazi, K; Flaig, TW; Kheoh, T; Li, J; Mulders, PFA; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Todd, MB	1
Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ	1
Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ	1
Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S	1
Abdallah, K; Airola, A; Aittokallio, T; Bare, JC; Bot, BM; Costello, JC; Friend, S; Guinney, J; Khan, SA; Laajala, TD; Mirtti, T; Neto, EC; Norman, T; Pahikkala, T; Peddinti, G; Ryan, CJ; Sartor, O; Scher, HI; Shen, L; Soule, H; Stolovitzky, G; Sweeney, CJ; Wang, T; Winner, KK; Xie, Y; Yu, T; Zhou, FL	1
Abdallah, K; Bates, SE; Beetsch, J; Curt, G; Fojo, T; Hugh-Jones, C; Lebowitz, P; Morrell, J; Murphy, M; Rothenberg, M; Sargent, DJ; Scher, HI; Simantov, R; Simon, R; Stein, WD; Wilkerson, J	1
Fan, JH; He, DL; Jiang, YM; Lv, W; Pei, XQ; Tian, G; Wu, DP; Wu, KJ	1
Clausse, M; D'Hondt, L; Demey, W; Everaert, E; Filleul, B; Gil, T; Goeminne, JC; Lumen, N; Machiels, JP; Mebis, J; Pelgrims, G; Rasschaert, M; Rottey, S; Schallier, D; Schatteman, P; Schrijvers, D; Van Aelst, F; Van Erps, J; Van Haverbeke, J; Van Hende, F; Van Praet, C; Verheezen, J; Vermeij, J; Werbrouck, P; Wynendaele, W	1
Bergman, AM; Blumenstein, B; Chi, KN; de Bono, JS; Ferrero, JM; Feyerabend, S; Gleave, M; Gravis, G; Higano, CS; Jacobs, C; Merseburger, AS; Mukherjee, SD; Reeves, J; Saad, F; Stenzl, A; Zalewski, P	1
Cicero, G; DE Luca, R; Dieli, F; Dorangricchia, P	1
Sidaway, P	1
Beeker, A; Bloemendal, HJ; de Klerk, JMH; Hoekstra, OS; Jonker, MA; Los, M; O'Sullivan, JM; Oprea-Lager, DE; van den Berg, HP; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW	1
Breaker, K; Flaig, TW; Gao, D; Kessler, ER; Lam, ET; Wacker, M; Wold, M	1
Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, MHA; Lara, PN; Mack, PC; Monk, JP; Plets, M; Pond, GR; Quinn, DI; Sonpavde, G; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ	1
Scott, LJ	1
Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A	1
Cicero, G; De Luca, R; Dieli, F	1
Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS	1
Cicero, G; Costa, RP; De Luca, R; Murabito, A; Tripoli, V	1
Cai, W; Chi, C; Dong, B; Fan, L; Pan, J; Qian, H; Shangguan, X; Shao, X; Wang, R; Wang, Y; Xu, F; Xue, W; Zhang, Y; Zhou, L; Zhu, Y	1
Ghatalia, P; Pond, GR; Sonpavde, G; Templeton, AJ	1
Elkon, JM; Lin, J; Millado, KF; Millett, RL	1
Baciarello, G; Fizazi, K; Hamilou, Z	1
Boerner, J; Dobson, K; Fontana, J; Heath, E; Heilbrun, L; Li, J; Smith, D; Stark, K; Thakur, MK; Vaishampayan, U	1
de Reijke, TM; Poorthuis, MHF; van Moorselaar, RJA; Vernooij, RWM	1
Campins, L; Font, A; Lianes, P; Marin, S; Miarons, M; Querol, R	1
Lei, BH; Lu, ZJ; Wang, Y; Zhang, Y; Zhu, QY; Zou, Q	1
Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR	1
Huang, C; Song, P; Wang, Y	1
Bejrananda, T; Karnjanawanichkul, W; Pripatnanont, C; Tanthanuch, M	1
Ma, Y; Newton, PK; West, J	1
Abogunrin, S; De Porre, P; Diels, J; Feyerabend, S; Fizazi, K; Ito, T; Koufopoulou, M; Li, T; Roiz, J; Saad, F; Van Sanden, S	1
Abdel-Rahman, O	1
Araujo, JC; Chi, KN; De Bono, JS; Dutta, S; Eisenberger, MA; Fizazi, K; George, DJ; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Morris, MJ; Petrylak, DP; Quinn, DI; Rosenthal, M; Small, EJ; Tangen, CM; Tannock, IF; Thompson, IM	1
Chi, C; Dong, B; Fan, L; Gong, Y; Ma, X; Pan, J; Wang, R; Xue, W; Yang, Y; Zheng, H; Zhu, Y	1
Abdallah, K; Bare, C; Costello, JC; Elo, LL; Fuchs, C; Gofer, E; Greiner, R; Guinney, J; Kanigel Winner, K; Koestler, DC; Kumar, L; Neto, EC; Norman, T; Piccolo, SR; Ryan, CJ; Sartor, O; Scher, HI; Seyednasrollah, F; Shen, L; Soule, HR; Stolovitzky, G; Sweeney, CJ; Vega, R; Wang, T; Wolfinger, RD; Yu, T; Zhou, FL	1
Amin, MB; Balogh, AG; Feng, FY; Garzotto, MG; Gomella, LG; Hannan, R; Horwitz, EM; Hu, C; Michalski, JM; Pervez, N; Peters, CA; Purdy, J; Raben, A; Reaume, MN; Rodrigues, GB; Rosenthal, SA; Sandler, HM; Sartor, O; Shipley, WU; Souhami, L; Williams, SG	1
Chen, E; Evans, A; Hansen, AR; Joshua, AM; Knox, J; Prawira, A; Sridhar, SS; Tan, S; Tannock, IF; Templeton, A; Vera-Badillo, F; Wang, L; Wouters, BG	1
Al-Janadi, A; Bolton, S; Flaig, T; Heath, E; Heilbrun, L; Hussain, A; Ivy, SP; Lara, P; Liu, G; Mack, P; Mannuel, H; Monk, JP; Silbiger, D; Smith, D; Stella, P; Usman, M; Vaishampayan, U; Zurita, A	1
Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X	1
Cuevas Sanz, JM; García García-Porrero, Á; González-Del-Alba, A; Méndez-Vidal, MJ; Muñoz Del Toro, JR; Pinto, A; Puente, J; Rodríguez, Á; Sala-Gonzalez, N; Useros Rodríguez, E; Vázquez, S	1
George, DJ	1
Anand, M; Armstrong, AJ; Barak, I; George, DJ; Halabi, S; Harrison, MR; Healy, P; Klein, M; Martinez, E; Nixon, AB; Szmulewitz, R; Wilder, R; Winters, C	1
Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F	1
Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M	1
Fong, L; Nicholson, LT	1
Dutta, S; Halabi, S; Kelly, WK; Middleberg, R; Morris, MJ; Russell, C; Ryan, CJ; Taplin, ME	1
Araujo, JC; Chi, KN; De Bono, JS; Dutta, S; Eisenberger, MA; Fizazi, K; Halabi, S; Higano, CS; Kelly, WK; Logothetis, C; Morris, MJ; Petrylak, DP; Quinn, DI; Rosenthal, M; Small, EJ; Tangen, CM; Tannock, IF; Thompson, IM	1
Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D	1
Cao, HF; Chen, DY; Cheng, L; Dong, JF; Dong, LX; Wang, Y; Yue, CF	1
Eterović, D; Omrčen, T; Vrdoljak, E	1
Chang, EM; Deville, C; Feng, FY; Kishan, AU; Koontz, BF; Nickols, NG; Ost, P; Parikh, NR; Phillips, R; Raldow, AC; Reiter, RE; Rettig, MB; Spratt, DE; Steinberg, ML; Tran, PT; Vapiwala, N	1
Miller, K	1
Al Harthy, M; Arlen, PM; Bilusic, M; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Hankin, A; Karzai, FH; Kim, JW; Lee, MJ; Lee, S; Madan, RA; Marte, JL; Owens, H; Peer, CJ; Petrylak, DP; Rosner, I; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB; Williams, M; Yuno, A	1
Hu, YC; Jiang, JH; Ma, L; Ma, Q; Wang, KY; Zhang, LL	1
Ayadi, M; Bahri, O; Berjeb, KK; Braham, M; Chakroun, N; Chtourou, S; Debbabi, L; Fadhlaoui, A; Hamdoun, M; Hannachi, H; Kacem, K; Zemni, Z; Zhioua, F	1
Anai, S; Fujimoto, K; Ichikawa, K; Miyake, M; Nakai, Y; Tanaka, N	1
Crehange, G; Geoffrois, L; Gravis, G; Hennequin, C; Kleinclauss, F; Limat, S; Morgans, AK; Nerich, V; Oudard, S; Pelloux-Prayer, R; Schiele, P; Thiery-Vuillemin, A	1
Kramer, G; Maj-Hes, A; Sevcenco, S; Szarvas, T	1
Aragón, IM; Attard, G; Brighi, N; Casadei, C; Castro, E; Conteduca, V; De Giorgi, U; Gonzalez-Billalabeitia, E; Gurioli, G; Jayaram, A; Lolli, C; Lozano, R; Marin-Aguilera, M; Mellado, B; Olmos, D; Romero-Laorden, N; Scarpi, E; Schepisi, G; Wetterskog, D; Wingate, A	1
Burgents, J; Chandana, SR; Facchini, G; Fizazi, K; Flaig, TW; Gafanov, R; Kramer, G; Li, B; Petrylak, DP; Piulats, JM; Ratta, R	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Aglietta, M; Aieta, M; Bozza, G; Buti, S; Caffo, O; Carrozza, F; Ciccarese, C; D'Angelo, A; De Giorgi, U; Ermacora, P; Facchini, G; Fratino, L; Galli, L; Gasparro, D; Giordano, M; Iacovelli, R; Kinspergher, S; Lippe, P; Lo Re, G; Maines, F; Maruzzo, M; Messina, C; Morelli, F; Mucciarini, C; Nicodemo, M; Nolè, F; Ortega, C; Palesandro, E; Pappagallo, G; Porta, C; Razzini, G; Rossetti, S; Sabbatini, R; Sartori, D; Scapoli, D; Schepisi, G; Valcamonico, F; Veccia, A; Verri, E; Vittimberga, I; Zagonel, V	1
Besson, D; Borchiellini, D; Bost, F; Cheli, S; Deville, JL; El Kouri, C; Ferrero, JM; Guillot, A; Hilgers, W; Hoch, B; Milano, G; Paoli, JB; Priou, F; Pujalte Martin, M; Schiappa, R; Tanti, JF; Thamphya, B	1
Pramod, SV; Safriadi, F; Tresnanda, RI	1
Ameye, F; Baekelandt, F; Bamelis, B; De Roock, W; Denies, E; Duck, L; Filleul, B; Fransis, K; Ghysel, C; Hollebosch, S; Joniau, S; Lambert, E; Logghe, P; Lumen, N; Ost, D; Remondo, C; Sautois, B; Schatteman, P; Van Bruwaene, S; van Praet, C; van Wambeke, S; Vandenbroucke, F; Vergauwe, E; Wynendaele, W	1
Bahl, A; Bartunkova, J; Beer, TM; Cheung, E; Csöszi, T; Feyerabend, S; Filipovic, Z; Fricke, H; Gerritsen, W; Goncalves, F; Hajek, J; Hussain, A; Hussain, S; Kadlecova, P; Khoo, V; Korolkiewicz, RP; Kukielka-Budny, B; Oudard, S; Prokhorov, A; Samal, V; Scheiner, T; Sousa, N; Spisek, R; Stenzl, A; Vogelzang, NJ; Wiechno, P	1
Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L	1
Appleman, LJ; Berry, WR; Bögemann, M; Conter, HJ; de Bono, JS; Emmenegger, U; Gravis, G; Gurney, H; Joshua, AM; Kolinsky, MP; Laguerre, B; Li, XT; Linch, M; Massard, C; Mourey, L; Piulats, JM; Poehlein, CH; Retz, M; Romano, E; Schloss, C; Sridhar, S; Yu, EY	1
Aieta, M; Airoldi, M; Ardizzoia, A; Beccaglia, P; Bonetti, A; Chiuri, VE; Conforti, S; D'Aniello, C; De Tursi, M; Di Lorenzo, G; Francolini, G; Fratino, L; Galli, L; Maestri, A; Muto, A; Petrioli, R; Pisconti, S; Quadrini, S; Rossetti, S; Satta, F; Sbrana, A; Scavelli, C; Sirotova, Z	1
Abadie-Lacourtoisie, S; Berdah, JF; Berthold, D; Bossi, A; Calabro, F; Carles, J; Chand-Fouche, ME; El Kouri, C; Escande, A; Fizazi, K; Fléchon, A; Foulon, S; Freixa, SV; Gravis, G; Hasbini, A; Jamaluddin, M; Kacso, G; Laguerre, B; Latorzeff, I; Magne, N; Martin, E; McDermott, R; Mourey, L; Priou, F; Rieger, I; Ronchin, P; Rosello, A; Roubaud, G; Schlurmann, F; Silva, M; Supiot, S; Thiery-Vuillemin, A; Tombal, B	1
Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P	1
Halabi, S; McSweeney, S; Morgans, AK; Oyenuga, A; Oyenuga, M; Prizment, A; Ryan, CJ	1
Azem, O; Camden, NB; Cueto-Marquez, AE; D'souza, LA; King, K; Kishan, AU; Malone, S; Morgan, SC; Roy, S; Saad, F; Spratt, DE; Sun, Y; Wallis, CJD; Zhou, YM	1
Kishan, AU; Le, ATT; Malone, J; Malone, S; Morgan, SC; Roy, S; Saad, F; Spratt, DE; Sun, Y; Wallis, CJD	1
Beckstead, R; Cutshall, ZA; Dougherty, M; Haaland, B; Kohli, M; Kohli, R; Nelson, RE; Yoo, M	1

Reviews

52 review(s) available for prednisone and docetaxel anhydrous

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[New antitumor drugs for non-Hodgkin's lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:14 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Paclitaxel; Prednisone; Rituximab; Taxoids; Vincristine	1998
Complications of chemotherapy for prostate cancer. Seminars in urologic oncology, 2001, Volume: 19, Issue:3 Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Gastrointestinal Diseases; Humans; Male; Mitoxantrone; Nervous System Diseases; Paclitaxel; Prednisone; Prostatic Neoplasms; Taxoids	2001
[Chemotherapy of the hormone-refractory prostate cancer]. Aktuelle Urologie, 2004, Volume: 35, Issue:3 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisone; Prostatic Neoplasms; Taxoids	2004
[Chemotherapy for prostate cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:2 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compounds; Docetaxel; Drug Resistance; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids	2005
Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy. European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2005
Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. The Canadian journal of urology, 2005, Volume: 12 Suppl 1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2005
Update in the management of patients with hormone-refractory prostate cancer. Current opinion in urology, 2005, Volume: 15, Issue:3 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; Estramustine; Humans; Male; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2005
[Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies]. Bulletin du cancer, 2005, May-01, Volume: 92, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2005
Which drug combination for hormone-refractory prostate cancer? Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:4 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids	2005
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology, 2005, Volume: 65, Issue:6 Suppl Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2005
Future directions in the treatment of androgen-independent prostate cancer. Urology, 2005, Volume: 65, Issue:6 Suppl Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Estramustine; Forecasting; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2005
An interdisciplinary approach to treating prostate cancer. Urology, 2005, Volume: 65, Issue:6 Suppl Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tosyl Compounds	2005
Current chemotherapeutic approaches for androgen-independent prostate cancer. Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A	2006
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Models, Economic; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome; United Kingdom	2007
[Prostate cancer and chemotherapy]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2007
Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert review of anticancer therapy, 2008, Volume: 8, Issue:2 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Immunotherapy; Infusions, Intravenous; Male; Neoplasm Invasiveness; Neoplasm Staging; Palliative Care; Prednisone; Prognosis; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Time Factors	2008
Chemotherapy in hormone-refractory prostate cancer. BJU international, 2008, Volume: 101 Suppl 2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nomograms; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids	2008
Management of metastatic prostate cancer: the crucial role of geriatric assessment. BJU international, 2008, Volume: 101 Suppl 2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Geriatric Assessment; Humans; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids	2008
[Problems and future direction of preoperative systemic therapy for patients with operable breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Nitriles; Prednisone; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Triazoles; Vincristine	2008
[Palliative systemic therapy of castration-resistant prostate cancer: current developments]. Der Urologe. Ausg. A, 2009, Volume: 48, Issue:11 Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Epothilones; Evidence-Based Medicine; Humans; Immunotherapy; Male; Neoplasm Staging; Orchiectomy; Palliative Care; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tubulin Modulators	2009
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate cancer and prostatic diseases, 2010, Volume: 13, Issue:2 Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Substance Withdrawal Syndrome; Taxoids; Treatment Outcome	2010
Angiogenesis inhibitors in the treatment of prostate cancer. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prednisone; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2010
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clinical interventions in aging, 2010, Dec-03, Volume: 5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Neutropenia; Prednisone; Prostatic Neoplasms; Rats; Taxoids	2010
Current clinical trials in castrate-resistant prostate cancer. Current urology reports, 2011, Volume: 12, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome	2011
Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs, 2012, Jul-30, Volume: 72, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	2012
Prostate cancer: The androgen receptor remains front and centre. Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:3 Topics: Abiraterone Acetate; Adenocarcinoma; Androgen Antagonists; Androgens; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Enzyme Inhibitors; Humans; Male; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids	2013
Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs, 2013, Volume: 73, Issue:18 Topics: Abiraterone Acetate; Androstadienes; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2013
Challenges in treating advanced disease. The American journal of managed care, 2013, Volume: 19, Issue:18 Suppl Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome	2013
Practical guide to the use of chemotherapy in castration resistant prostate cancer. The Canadian journal of urology, 2014, Volume: 21, Issue:2 Supp 1 Topics: Antineoplastic Agents; Docetaxel; Drug Therapy; Drug Therapy, Combination; Humans; Male; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome	2014
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone]. Bulletin du cancer, 2014, Volume: 101, Issue:4 Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Cells, Circulating; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids	2014
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids	2014
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Oct-20, Volume: 32, Issue:30 Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Taxoids	2014
Corticosteroids in the management of prostate cancer: a critical review. Current treatment options in oncology, 2015, Volume: 16, Issue:2 Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2015
[Posterior reversible encephalopathy syndrome after neurosurgery: A literature review]. Revista espanola de anestesiologia y reanimacion, 2015, Volume: 62, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blindness, Cortical; Brain Neoplasms; Craniotomy; Docetaxel; Epilepsy, Tonic-Clonic; Frontal Lobe; Humans; Hypertension; Male; Middle Aged; Paresis; Posterior Leukoencephalopathy Syndrome; Postoperative Complications; Prednisone; Prostatic Neoplasms; Taxoids	2015
A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature. Tumori, 2015, Jun-25, Volume: 101, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents; Antineoplastic Agents; Blood Gas Analysis; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Prednisone; Recovery of Function; Spirometry; Taxoids; Tomography, X-Ray Computed	2015
[How to manage patients with CRPC?]. Bulletin du cancer, 2015, Volume: 102, Issue:6 Topics: Abiraterone Acetate; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Tissue Extracts	2015
A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials. Scientific data, 2016, May-10, Volume: 3 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2016
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. Cancer treatment reviews, 2017, Volume: 55 Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Evidence-Based Medicine; Health Status; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Patient Selection; Population Surveillance; Prednisone; Prostatic Neoplasms; Taxoids; Tumor Burden; Uncertainty	2017
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer. Drugs, 2017, Volume: 77, Issue:14 Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant	2017
Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Aged; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Prednisone; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2018
Treatment of Castration-naive Metastatic Prostate Cancer. European urology focus, 2017, Volume: 3, Issue:6 Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2017
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. Seminars in oncology, 2017, Volume: 44, Issue:5 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic	2017
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 05-01, Volume: 29, Issue:5 Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2018
The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. International journal of surgery (London, England), 2018, Volume: 56 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Network Meta-Analysis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2018
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European journal of cancer (Oxford, England : 1990), 2018, Volume: 103 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic	2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 02-10, Volume: 37, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; White People	2019
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Clinical drug investigation, 2020, Volume: 40, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Ethnicity; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2020
Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:12 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts	2020
Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review. Asian Pacific journal of cancer prevention : APJCP, 2021, Oct-01, Volume: 22, Issue:10 Topics: Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Prednisolone; Prednisone; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies	2021
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective. Journal of the National Cancer Institute, 2023, Nov-08, Volume: 115, Issue:11 Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Bayes Theorem; Cost-Effectiveness Analysis; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023

Trials

113 trial(s) available for prednisone and docetaxel anhydrous

Article	Year
Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer, 1995, Feb-15, Volume: 75, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Premedication; Survival Rate; Taxoids	1995
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. American journal of clinical oncology, 2000, Volume: 23, Issue:2 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cohort Studies; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Prednisone; Taxoids	2000
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine, 2004, Oct-07, Volume: 351, Issue:15 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids	2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine, 2004, Oct-07, Volume: 351, Issue:15 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids	2004
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Approval; Drug Interactions; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; United States; United States Food and Drug Administration	2004
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids	2005
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome	2005
Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer? Nature clinical practice. Oncology, 2005, Volume: 2, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2005
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer? Nature clinical practice. Oncology, 2005, Volume: 2, Issue:2 Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Mitoxantrone; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2005
Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer Clinical genitourinary cancer, 2005, Volume: 4, Issue:3 Topics: Adrenal Cortex Hormones; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Humans; Male; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome	2005
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids	2006
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome	2007
Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Japanese journal of clinical oncology, 2007, Volume: 37, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids	2007
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Comorbidity; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Pain; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids	2007
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21 Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Analysis; Taxoids; Treatment Outcome	2007
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. British journal of cancer, 2007, Dec-17, Volume: 97, Issue:12 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids	2007
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome	2008
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, May-01, Volume: 14, Issue:9 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids	2008
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids	2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU international, 2008, Aug-05, Volume: 102, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome	2008
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Belgium; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome	2008
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009, Volume: 18, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Models, Statistical; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2009
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds	2009
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival. International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid	2009
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids	2010
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Orchiectomy; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome	2010
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational new drugs, 2011, Volume: 29, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Integrin alphaV; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome	2011
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-20, Volume: 28, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome	2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-20, Volume: 28, Issue:12 Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Down-Regulation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Middle Aged; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Time Factors; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays	2010
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Oligodeoxyribonucleotides; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome	2011
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-20, Volume: 28, Issue:27 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Clusterin; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Orchiectomy; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Taxoids; Thionucleotides; Time Factors; Treatment Failure; Washington	2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England), 2010, Oct-02, Volume: 376, Issue:9747 Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Neutropenia; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome	2010
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer. Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:3 Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome	2010
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. British journal of cancer, 2011, Feb-15, Volume: 104, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure	2011
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Failure	2011
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Humans; Male; Prednisone; Prostatic Neoplasms; Salvage Therapy; Taxoids	2011
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer]. Der Urologe. Ausg. A, 2011, Volume: 50, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Germany; Humans; Male; Oligonucleotides, Antisense; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thionucleotides	2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Thionucleotides; Treatment Outcome	2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids	2012
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. British journal of cancer, 2011, Nov-22, Volume: 105, Issue:11 Topics: Administration, Oral; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids	2011
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Treatment Outcome	2012
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 2012, Volume: 10, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Exanthema; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Orchiectomy; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome	2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-01, Volume: 30, Issue:13 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Placebos; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome; United States	2012
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. Urologic oncology, 2013, Volume: 31, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2013
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2012
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone	2012
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2012, Volume: 50, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 2012, Volume: 10, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neutropenia; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids	2012
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Integrin alphaV; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Survival; Taxoids	2013
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4 Topics: Abiraterone Acetate; Androstadienes; Castration; Docetaxel; Fatigue; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Surveys and Questionnaires; Taxoids	2013
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. Clinical genitourinary cancer, 2013, Volume: 11, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Polymorphism, Single Nucleotide; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1	2013
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. The Lancet. Oncology, 2013, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; North America; Orchiectomy; Prednisone; Proportional Hazards Models; Prostatic Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; South America; Taxoids; Time Factors; Treatment Outcome	2013
Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clinical genitourinary cancer, 2013, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Docetaxel; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Position-Specific Scoring Matrices; Prednisone; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Survival; Taxoids	2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer, 2013, Oct-15, Volume: 119, Issue:20 Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; International Agencies; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids	2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer, 2011, Jun-01, Volume: 117, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome	2011
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. American journal of clinical oncology, 2015, Volume: 38, Issue:5 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2015
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2014, Volume: 17, Issue:1 Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Treatment Outcome; Viscera	2014
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. European urology, 2014, Volume: 65, Issue:5 Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Fatigue; Humans; Hypertension; Hypokalemia; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids	2014
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22 Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Models, Statistical; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Pain; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Taxoids; Treatment Outcome	2013
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24 Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Approval; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome; United States; United States Food and Drug Administration	2013
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. BJU international, 2015, Volume: 115, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine	2015
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. European urology, 2014, Volume: 65, Issue:3 Topics: Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Humans; Male; Oligonucleotides; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU international, 2014, Volume: 114, Issue:6b Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors	2014
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jan-10, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome	2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids	2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. European urology, 2015, Volume: 67, Issue:5 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids	2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clinical genitourinary cancer, 2015, Volume: 13, Issue:1 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; DNA Methylation; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasm Metastasis; Nuclear Proteins; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome	2015
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer, 2015, Apr-01, Volume: 121, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Bevacizumab; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thromboembolism; Venous Thromboembolism	2015
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Follow-Up Studies; Humans; International Agencies; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutrophils; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids	2015
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Investigational new drugs, 2015, Volume: 33, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone	2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Clinical genitourinary cancer, 2015, Volume: 13, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome	2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Naphthalenes; Neoplasm Grading; North America; Odds Ratio; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2015
A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PloS one, 2015, Volume: 10, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome	2015
A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer. Chemotherapy, 2014, Volume: 60, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2014
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide	2015
Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure. The oncologist, 2015, Volume: 20, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids	2015
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget, 2015, Jul-20, Volume: 6, Issue:20 Topics: Adenocarcinoma; Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dendritic Cells; Docetaxel; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Nomograms; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Risk Factors; T-Lymphocyte Subsets; Taxoids; Time Factors; Treatment Outcome	2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:13 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Ramucirumab; Taxoids; Time Factors; Treatment Outcome; United States; Young Adult	2015
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology, 2015, Volume: 86, Issue:6 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Everolimus; Humans; Male; Neoplastic Cells, Circulating; Phosphorylation; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins	2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European urology, 2016, Volume: 69, Issue:5 Topics: Abiraterone Acetate; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Survival Rate; Taxoids	2016
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1 Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids	2016
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology, 2016, Volume: 90, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromogranin A; Curcumin; Docetaxel; Geriatric Assessment; Humans; Male; Medication Adherence; Middle Aged; Phosphopyruvate Hydratase; Pilot Projects; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Treatment Outcome	2016
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. European journal of cancer (Oxford, England : 1990), 2016, Volume: 56 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Kallikreins; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Neutrophils; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Severity of Illness Index; Taxoids; Time Factors; Treatment Outcome	2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. European urology, 2016, Volume: 70, Issue:5 Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2016
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. International journal of urology : official journal of the Japanese Urological Association, 2016, Volume: 23, Issue:5 Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-01, Volume: 22, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Double-Blind Method; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Polyneuropathies; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2016
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. European urology, 2017, Volume: 71, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide	2017
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA oncology, 2017, Jan-01, Volume: 3, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide	2017
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. The Lancet. Oncology, 2017, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Crowdsourcing; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Nomograms; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Young Adult	2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. The Lancet. Oncology, 2017, Volume: 18, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thionucleotides	2017
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. Anticancer research, 2017, Volume: 37, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Taxoids; Treatment Outcome	2017
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organometallic Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph The Lancet. Oncology, 2017, Volume: 18, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thionucleotides; Tomography, X-Ray Computed; Treatment Outcome	2017
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Somatostatin; Treatment Outcome	2018
[Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer]. Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:10 Topics: Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Goserelin; Humans; Male; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tosyl Compounds; Treatment Outcome	2017
Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies. Clinical genitourinary cancer, 2019, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Docetaxel; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 05-10, Volume: 37, Issue:14 Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Survival Rate	2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). The oncologist, 2019, Volume: 24, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pantoprazole; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. The oncologist, 2019, Volume: 24, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A	2019
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. The Prostate, 2019, Volume: 79, Issue:15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sulfonamides; Survival Rate; Treatment Outcome	2019
Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. Clinical genitourinary cancer, 2020, Volume: 18, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU international, 2021, Volume: 127, Issue:4 Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyridines; Treatment Outcome	2021
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future oncology (London, England), 2021, Volume: 17, Issue:25 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prednisolone; Prednisone; Progression-Free Survival; Prostate; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic	2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European urology, 2021, Volume: 80, Issue:4 Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. European journal of cancer (Oxford, England : 1990), 2021, Volume: 155 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Female; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant	2021
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2021, Volume: 19, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Metformin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Treatment Outcome	2021
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. JAMA oncology, 2022, 04-01, Volume: 8, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Double-Blind Method; Female; Humans; Immunotherapy; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant	2022
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 04-14, Volume: 28, Issue:8 Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Docetaxel; Febrile Neutropenia; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Purines; Treatment Outcome	2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. European urology, 2022, Volume: 82, Issue:1 Topics: Abiraterone Acetate; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2022
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet (London, England), 2022, 04-30, Volume: 399, Issue:10336 Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Hypertension; Male; Prednisone; Prostatic Neoplasms	2022
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:10 Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone	2022
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. European urology, 2023, Volume: 83, Issue:6 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Receptors, Androgen; Treatment Outcome	2023
Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer. The Prostate, 2023, Volume: 83, Issue:10 Topics: Docetaxel; Humans; Male; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant	2023

Other Studies

87 other study(ies) available for prednisone and docetaxel anhydrous

Article	Year
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Seminars in oncology, 1999, Volume: 26, Issue:5 Suppl 17 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids	1999
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast cancer research : BCR, 2004, Volume: 6, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine	2004
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival]. Aktuelle Urologie, 2005, Volume: 36, Issue:5 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Time Factors	2005
Potential role of inhibiting the vascular endothelial growth factor pathway in advanced prostate cancer. Clinical prostate cancer, 2005, Volume: 4, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids; Vascular Endothelial Growth Factor A	2005
[Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone]. Nederlands tijdschrift voor geneeskunde, 2005, Oct-29, Volume: 149, Issue:44 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome	2005
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. Journal of the National Cancer Institute, 2006, Apr-19, Volume: 98, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Taxoids; Time Factors	2006
A prospective investigation of chemotherapy-induced neutropenia and quality of life. The journal of supportive oncology, 2006, Volume: 4, Issue:9 Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Cisplatin; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Prednisone; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Regression Analysis; Severity of Illness Index; Sickness Impact Profile; Taxoids; Treatment Outcome; United States; Vincristine	2006
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. BJU international, 2007, Volume: 100, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2007
[Effects of docetaxel and prednisone for hormone-refractory prostate cancer]. Zhonghua yi xue za zhi, 2007, Jun-26, Volume: 87, Issue:24 Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Humans; Karnofsky Performance Status; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2007
Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center. Urologia internationalis, 2007, Volume: 79, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Failure; Treatment Outcome	2007
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-10, Volume: 25, Issue:35 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Meta-Analysis as Topic; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids	2007
Efficacy vs. effectiveness--docetaxel and prednisone in hormone refractory prostate cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2008, Volume: 14, Issue:1 Topics: Aged; Aged, 80 and over; Alberta; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids	2008
The postchemotherapy PSA surge syndrome. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome	2008
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Journal of the National Cancer Institute, 2008, May-07, Volume: 100, Issue:9 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Taxoids; Treatment Outcome	2008
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate cancer and prostatic diseases, 2009, Volume: 12, Issue:1 Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Obesity; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Testosterone; Treatment Outcome	2009
Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU international, 2008, Volume: 102, Issue:11 Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids	2008
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-10, Volume: 27, Issue:17 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Epothilones; Humans; Infusions, Subcutaneous; Male; Middle Aged; Military Personnel; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2009
[A squamous cell lung cancer patient who developed immune hemolytic anemia after gemcitabine and docetaxel administration]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:7 Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Prednisone; Taxoids	2009
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid	2009
Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. American journal of clinical oncology, 2011, Volume: 34, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Florida; Humans; Hyperglycemia; Kaplan-Meier Estimate; Linear Models; Lymphoma, Non-Hodgkin; Male; Medical Records; Middle Aged; Neoplasm Staging; Prednisone; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Rituximab; Taxoids; Treatment Outcome; Vincristine	2011
Transverse ridging of the nails. Internal medicine journal, 2010, Volume: 40, Issue:9 Topics: Aged; Docetaxel; Humans; Male; Nail Diseases; Prednisone; Taxoids	2010
Cabazitaxel in prostate cancer: stretching a string. Lancet (London, England), 2010, Oct-02, Volume: 376, Issue:9747 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Tissue Extracts	2010
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer biology & therapy, 2010, Dec-15, Volume: 10, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids; Tubulin	2010
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology, 2011, Volume: 77, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Taxoids	2011
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU international, 2011, Volume: 107 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Epidemiologic Methods; Humans; Immunotherapy; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prognosis; Prostatectomy; Prostatic Neoplasms; Retreatment; Taxoids; Treatment Outcome	2011
[Study to castrate-resistant prostate cancer: AUO study AP 60/10]. Der Urologe. Ausg. A, 2011, Volume: 50, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Lenalidomide; Male; Prednisone; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Failure	2011
Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience. European review for medical and pharmacological sciences, 2011, Volume: 15, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome	2011
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European urology, 2012, Volume: 61, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Gossypol; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome	2012
Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9. European urology, 2012, Volume: 61, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Gossypol; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids	2012
[Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute]. Hinyokika kiyo. Acta urologica Japonica, 2011, Volume: 57, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2011
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]. Der Urologe. Ausg. A, 2012, Volume: 51, Issue:3 Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids	2012
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. European urology, 2013, Volume: 63, Issue:6 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Fever; Germany; Humans; Kallikreins; Male; Middle Aged; Neutropenia; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Treatment Failure; Treatment Outcome	2013
Abiraterone and its place in the treatment of metastatic CRPC. Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:1 Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome	2013
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: 14-alpha Demethylase Inhibitors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome	2013
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:15 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Multicenter Studies as Topic; Netherlands; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risedronic Acid; Survival Analysis; Taxoids	2013
Major response to cyclophosphamide and prednisone in recurrent castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Volume: 11, Issue:8 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2013
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer. Urology, 2013, Volume: 82, Issue:5 Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androstadienes; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2013
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prednisone; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Tumor Burden	2013
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2013
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Docetaxel; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nomograms; Orchiectomy; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation; Reproducibility of Results; Risk Assessment; Risk Factors; Taxoids	2014
Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. International urology and nephrology, 2014, Volume: 46, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2014
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Cohort Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infection Control; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Risk Factors; Rituximab; Taxoids; Vincristine; Young Adult	2014
Beau's lines of the fingernails. The American journal of the medical sciences, 2015, Volume: 349, Issue:4 Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Nail Diseases; Nails; Prednisone; Prostatic Neoplasms; Taxoids	2015
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:12 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Drug Monitoring; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Male; Middle Aged; Patient Selection; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Severity of Illness Index; Taxoids; Treatment Outcome	2014
Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1 Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Salvage Therapy; Taxoids	2015
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome	2015
Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. Annals of palliative medicine, 2015, Volume: 4, Issue:2 Topics: Aged; Antineoplastic Agents; Blood Glucose; Comorbidity; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Hyperglycemia; Male; Monitoring, Physiologic; Ontario; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids; Urinary Bladder Neoplasms; Urogenital Neoplasms	2015
[Predictor analysis of PSA response of docetaxel combined with prednisone in the treatment of metastatic castration resistant prostate cancer]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2015, Aug-18, Volume: 47, Issue:4 Topics: Disease Progression; Docetaxel; Humans; Lymphatic Metastasis; Male; Neoplasm Grading; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2015
Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer. Oncotarget, 2015, Dec-08, Volume: 6, Issue:39 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Count; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Risk Factors; Serum Albumin; Serum Albumin, Human; Taxoids; Time Factors; Treatment Outcome	2015
Ureteral Metastasis: Uncommon Manifestation in Prostate Cancer. Anticancer research, 2015, Volume: 35, Issue:11 Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Ureteral Neoplasms	2015
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2016
Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Journal of oncology practice, 2016, Volume: 12, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cluster Analysis; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; National Cancer Institute (U.S.); Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; United States	2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European urology, 2017, Volume: 71, Issue:4 Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Practice Patterns, Physicians'; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids	2017
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. The Lancet. Oncology, 2017, Volume: 18, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Taxoids	2017
Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China. International urology and nephrology, 2017, Volume: 49, Issue:4 Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Docetaxel; Humans; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Neutrophils; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Serum Albumin; Survival Rate; Taxoids; Treatment Outcome	2017
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel? Clinical genitourinary cancer, 2017, Volume: 15, Issue:4 Topics: Abiraterone Acetate; Aged; Docetaxel; Humans; Male; Prednisone; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; ROC Curve; Survival Analysis; Taxoids; Treatment Outcome	2017
Prostate cancer: Custirsen fails to improve outcomes. Nature reviews. Urology, 2017, Volume: 14, Issue:6 Topics: Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thionucleotides	2017
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 03-01, Volume: 28, Issue:3 Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Response Evaluation Criteria in Solid Tumors; Survival Analysis; Taxoids	2017
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study. Anti-cancer drugs, 2017, Volume: 28, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2017
Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer. Oncology, 2017, Volume: 93, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Phenylurea Compounds; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome	2017
The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. Oncology, 2018, Volume: 94, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Italy; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Retrospective Studies; Taxoids	2018
Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. The Prostate, 2018, Volume: 78, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Systemic Inflammatory Response Syndrome; Treatment Outcome	2018
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:5 Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2018
Long-term abiraterone withdrawal syndrome. Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:5 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Substance Withdrawal Syndrome; Treatment Outcome	2018
Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2016, Volume: 99, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2016
Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. Journal of theoretical biology, 2018, 10-14, Volume: 455 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Models, Biological; Prednisone; Prostatic Neoplasms, Castration-Resistant	2018
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. The Prostate, 2019, Volume: 79, Issue:6 Topics: Abiraterone Acetate; Aged; Antigens, Differentiation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Monitoring; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant	2019
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer. JCO clinical cancer informatics, 2017, Volume: 1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Middle Aged; Models, Theoretical; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome; Young Adult	2017
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. The Prostate, 2019, Volume: 79, Issue:13 Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2019
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC cancer, 2019, Aug-05, Volume: 19, Issue:1 Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Docetaxel; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Pain; Prednisone; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Spain; Taxoids; Treatment Outcome	2019
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy. Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:7 Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid	2019
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. British journal of cancer, 2019, Volume: 121, Issue:12 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2019
Immune Checkpoint Inhibition in Prostate Cancer. Trends in cancer, 2020, Volume: 6, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Prednisone; Programmed Cell Death 1 Receptor; Prostatic Neoplasms	2020
Can docetaxel combined prednisone effectively treat hormone refractory prostate cancer?: A protocol of systematic review and meta-analysis. Medicine, 2020, May-29, Volume: 99, Issue:22 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisone; Prostatic Neoplasms; Systematic Review as Topic	2020
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. Anti-cancer drugs, 2020, Volume: 31, Issue:7 Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. International journal of radiation oncology, biology, physics, 2020, 11-15, Volume: 108, Issue:4 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Confidence Intervals; Cost-Benefit Analysis; Docetaxel; Humans; Male; Markov Chains; Monte Carlo Method; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Salvage Therapy; Time Factors	2020
[Sequential therapy for asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer]. Aktuelle Urologie, 2020, Volume: 51, Issue:6 Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2020
Efficacy and safety of docetaxel and prednisolone chemotherapy in very elderly men with metastatic castration-resistant prostate cancer (mCRPC) in real world: a single institute experience. Annals of palliative medicine, 2021, Volume: 10, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Docetaxel; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2021
Evaluation of ovarian reserve before and after chemotherapy. Journal of gynecology obstetrics and human reproduction, 2021, Volume: 50, Issue:5 Topics: Adolescent; Adult; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacarbazine; Docetaxel; Doxorubicin; Epirubicin; Etoposide; Female; Fertility Preservation; Fluorouracil; Hodgkin Disease; Humans; Longitudinal Studies; Luminescent Measurements; Ovarian Reserve; Prednisone; Procarbazine; Vinblastine; Vincristine; Young Adult	2021
Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. Chemotherapy, 2020, Volume: 65, Issue:5-6 Topics: Aged; Aged, 80 and over; Dexamethasone; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2020
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. Clinical genitourinary cancer, 2021, Volume: 19, Issue:5 Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Markov Chains; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Therapies, Investigational; Treatment Outcome	2021
Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival. Advances in therapy, 2021, Volume: 38, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kinetics; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Treatment Outcome	2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. European journal of cancer (Oxford, England : 1990), 2021, Volume: 152 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prednisone; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2021
Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis. Acta clinica Belgica, 2022, Volume: 77, Issue:6 Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Belgium; Data Analysis; Docetaxel; Hormones; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome	2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry. Tumori, 2023, Volume: 109, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Treatment Outcome	2023
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. The Prostate, 2023, Volume: 83, Issue:7 Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Pain; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome	2023